Stress Mediators and Immune Dysfunction in Patients with Acute Cerebrovascular Diseases

Arthur Liesz1*, Holger Rüger1, Jan Purrucker1, Markus Zorn2, Alexander Dalpke3, Markus Möhlenbruch4, Stefan Englert5, Peter P. Nawroth2, Roland Veltkamp1

1 Department of Neurology, University Heidelberg, Heidelberg, Germany, 2 Department of Internal Medicine, University Heidelberg, Heidelberg, Germany, 3 Department of Infectious Diseases, Medical Microbiology and Hygiene, University Heidelberg, Heidelberg, Germany, 4 Department of Neuroradiology, University Heidelberg, Heidelberg, Germany, 5 Institute of Medical Biometry and Informatics, University Heidelberg, Heidelberg, Germany

Abstract

Background: Post-stroke immune depression contributes to the development of infections which are major complications after stroke. Previous experimental and clinical studies suggested that humoral stress mediators induce immune dysfunction. However, prospective clinical studies testing this concept are missing and no data exists for other cerebrovascular diseases including intracerebral hemorrhage (ICH) and TIA.

Methods: We performed a prospective clinical study investigating 166 patients with TIA, ischemic and hemorrhagic stroke. We measured a broad panel of stress mediators, leukocyte subpopulations, cytokines and infection markers from hospital admission to day 7 and on follow-up after 2–3 months. Multivariate regression analyses detected independent predictors of immune dysfunction and bacterial infections. ROC curves were used to test the diagnostic value of these parameters.

Results: Only severe ischemic strokes and ICH increased some catecholamine metabolites, ACTH and cortisol levels. Immunodeficiency was eminent already on hospital admission after large brain lesions with lymphocytopenia as a key feature. None of the stress mediators was an independent predictor of lymphocytopenia or infections. However, lymphocytopenia on hospital admission was detected as an independent explanatory variable of later infections. NIHSSS and lymphocytopenia on admission were excellent predictors of infection.

Conclusions: Our results question the present pathophysiological concept of stress-hormone mediated immunodysfunction after stroke. Early lymphocytopenia was identified as an early independent predictor of post-stroke infections. Absence of lymphocytopenia may serve as a negative predictive marker for stratification for early antibiotic treatment.

Introduction

Infectious complications are a leading cause of morbidity and mortality after stroke [1,2]. The most common infections are pneumonia and urinary tract infections. Nearly all pneumonias occur within the first week after stroke [3]. Besides well-known risk factors for pneumonia including stroke severity, age and dysphagia [4] a stroke-induced immunosuppression syndrome (SIDS) has been identified. Lymphocytopenia and reduced lymphocyte and monocyte function are the hallmarks of this syndrome [5–9]. SIDS has been associated with a substantially increased susceptibility to bacterial infections in experimental stroke models and stroke patients [10,11]. These effects depend on lesion size and were observed mainly after large ischemic stroke [12,13].

Already early clinical observations described the influence of brain ischemia on peripheral immune cells and proposed the sympathetic nervous system as the mediator of brain-immune interaction14, 15. Indeed, an increase of stress mediators including catecholamines and cortisol can be detected in stroke patients with extensive brain lesions [6,14,15]. Also, pharmacological blockade of beta-adrenergic receptors in experimental ischemia studies resulted in a partial normalization of immunological impairment [8]. These results led to the current concept that acute brain lesions result in an increased release of catecholamines and corticosteroids which downregulate the peripheral immune system and increase the susceptibility to infections [7,10,11,16].

A detailed review of the data underlying this concept reveals important limitations. Stress mediators have not been adequately established as independent predictors of post-stroke infections in clinical studies. Evidence for a causal relationship between the humoral stress response and immunomodulation in stroke comes from a single experimental study [8] using pharmacological blockade of catecholamine and glucocorticoid receptors only. Moreover, the concept has not been examined in other common cerebrovascular diseases such as transient ischemic attacks (TIA).
and intracerebral hemorrhage (ICH) which also induce peripheral immune changes [17].

We conducted a prospective study investigating the correlation and independent predictors of stress mediators, cellular and humoral immune markers and infectious complications in patients with TIA, ischemic stroke, and ICH compared to matched controls.

### Methods

The study was designed as a prospective, single center observational study conducted from 10/2011 until 11/2012 and was approved by the local ethics committee of the University Heidelberg (S-548/2011). All procedures were performed after written informed consent was obtained by the patient or a legal representative. Inclusion criteria were study enrollment within 24 h after symptom-onset resulting from a transient ischemic attack (TIA), ischemic stroke or intracerebral hemorrhage (ICH). Exclusion criteria were recent clinical infection (fever, cough, antibiotic treatment, laboratory markers) within 14d prior to admission, a chronic immunological disorder, preexisting immunosuppression, cancer and pregnancy.

For the control group, patients were included that presented at the Department of Ophthalmology for pre-surgical screening for cataract operation. Patients were selected to be in the same range for age and gender of patients with cerebrovascular disorders. Clinical data and blood markers were assessed for control patients by the same procedures as for patients with cerebrovascular disorders except for 24-hour urine collection. Blood was obtained only once in control patients.

Patients received routine cranial imaging by CT (Somatom Sensation 16) and/or 3 T MRI (Trio and/or Verio; all Siemens Medical Systems) to detect ischemic or hemorrhagic brain lesions. In TIA patients cerebral infarction was ruled out by MRI. The earliest image revealing the diagnosis was used to assess ischemic lesion or hematoma volume, when repeated images where performed, the one with the largest lesion demarcation was used for volumetry. Volume was calculated by integrating areas on each image multiplied by section diameter using a Syngo Multimodality workplace with syngoMMWP-software (version VE31A, Siemens).

Patients with cerebrovascular diseases underwent blood sampling on admission (day 1), days 2, 3 and 7, and at follow-up at 60–90 days later. We measured serum catecholamines and metabolites, ACTH, cortisol, differential blood cell count, cytokines, CRP and high sensitivity procalcitonin (hsPCT) in the central laboratory of the University Hospital Heidelberg by the same procedures as for patients with cerebrovascular disorders except for a 24-hour urine collection. Blood was obtained only once in control patients.

Routine microbiological analyses, chest x-ray and further examinations related to infectious complications were documented for the first 7d. In case of clinical and/or laboratory signs of infection, all patients received aerobic and anaerobic cultures of blood, sputum, tracheal aspirate, bronchoalveolar lavage, cerebrospinal fluid (CSF) or urine, respectively, at the treating physician's discretion. Positive bacterial infection was scored only in case of positive microbiological analysis, indicated by one of the following: presence of typical pathogenic bacteria, significant numbers of colony-forming units (CFU) for facultative pathogenic bacteria excluding sample contamination or any positive bacterial infection.

### Table 1. Clinical characteristics of patients used for analysis in the control, transient ischemic attack (TIA), ischemic stroke (stroke) and intracerebral hemorrhage (ICH) group.

| Clinical characteristics | Control | TIA | Stroke | ICH | p value |
|-------------------------|---------|-----|--------|-----|---------|
| n (total: 166)          | 30      | 23  | 70     | 43  |         |
| Age (years)             | 70±6.8  | 63.0±10.9 | 69.1±10.6 | 66.8±14.3 | 0.096  |
| Gender (male/female)    | 15/15   | 17/6 | 41/29  | 25/18| 0.371  |
| Lesion Volume (ml)      | 0       | 0   | 90±122 | 33±33| 0.577  |
| Median lesion volume (ml)| n.a.   | n.a.| 21.6   | 20.4 |         |
| Laterality (right/left) | n.a.    | 11/12| 31/39  | 25/18| 0.356  |
| NIHSSS at admission     | 0       | 0.2±0.5 | 12.2±7.9 | 16.6±11.8| 0.134  |
| Symptom to d1 time (h)  | n.a.    | 12.3±7.6| 12.9±7.9 | 10.1±7.5| 0.169  |
| Catecholamine treatment | n.a.    | 0   | 13 (19%)| 19 (44%)| 0.003  |
| Mortality (on day 7)    | n.a.    | 0   | 5 (7%)  | 1 (2%) | 0.254  |
| Mortality (on follow up)| n.a.    | 0   | 11 (16%)| 6 (14%)| 0.129  |
| Follow up survivors     | n.a.    | 17 (74%)| 48 (81%)| 28 (76%)| 0.694  |
| Pre-existing condition at admission |         |       |         |       |
| Dysslipidemia            | 9 (30%) | 5 (22%)| 19 (27%)| 8 (19%)| 0.649  |
| Arterial hypertension    | 26 (87%)| 17 (74%)| 44 (63%)| 27 (63%)| 0.086  |
| Diabetes                 | 9 (30%) | 4 (17%)| 23 (33%)| 6 (14%)| 0.095  |
| Smoking                  | 2 (7%)  | 5 (22%)| 15 (21%)| 8 (19%)| 0.336  |
| Prev. cardiovas. event   | 2 (7%)  | 7 (30%)| 22 (31%)| 11 (26%)| 0.065  |
| Atrial fibrillation      | 2 (7%)  | 3 (13%)| 21 (30%)| 5 (12%)| 0.014  |
| Premedication at admission|        |       |         |       |
| J-AR blocker            | 12 (4%) | 7 (30%)| 27 (39%)| 12 (28%)| 0.597  |
| Oral anticoagulants      | 7 (23%) | 1 (4%) | 13 (18%)| 7 (16%)| 0.305  |
| Antiplatelet drug        | 8 (27%) | 11 (48%)| 17 (24%)| 11 (26%)| 0.167  |
| Sympathetic nervous system drugs | 4 (13%)| 1 (4%) | 4 (6%)  | 2 (5%) | 0.434  |

# Notes:

1. previous TIA, stroke or myocardial infarction;
2. phenprocoumon, rivaroxaban;
3. aspirin, aspirin+dipyridamole, clopidogrel;
4. clonidin, oxybutinin, inhahle J-AR agonists, doxazosin, terazosin.
3. Metric data is shown as mean±SD, non-metric values as absolute numbers and percentage.
4. U test for stroke and ICH;
5. t test square test for TIA, stroke and ICH;
6. t test square test for stroke and ICH.

10.3137/journal.pone.0074839.t001
Figure 1. Humoral stress response in patients with acute cerebrovascular diseases. Blood plasma concentrations of indicated catecholamines and metanephrines were analyzed in (A) all patients (n = 166) or (B) only in patients not receiving catecholamine treatment (n = 134). Urin excretion of noradrenalin, metanephrines and vanillylmandelic acid (VMA) within the first 24 h after admission was investigated (C) in all patients with cerebrovascular events (left) or after exclusion of patients receiving catecholamine treatment during the urine collection period (right). (D) To investigate the HPA-axis, blood plasma concentrations of ACTH and cortisol were measured at the indicated time points after cerebrovascular events and in control patients. Group differences for all parameters were analyzed by Kruskal-Wallis H-test and Dunn’s post hoc test. Data is presented as median and interquartile range. * indicates significant (p<0.05) difference of the indicated group compared to the control group; horizontal bars indicate significant differences among groups at the respective time point.

doi:10.1371/journal.pone.0074839.g001
Figure 2. Alterations of the immune system after cerebrovascular events. (A) Changes of the cellular immune system were measured by the relative lymphocyte fraction, absolute lymphocyte counts, total leukocyte number and the absolute monocyte cell counts in control patients and at the indicated time points after cerebrovascular events. (B) Blood plasma concentrations of IL-10, IL-6 and IL-1β were determined to analyze humoral mediators of immune function. Blood cell counts and cytokines were analyzed by analysis of variance (ANOVA) after testing for normal distribution. Data are presented as mean±/− standard deviation. * indicates a significant (p<0.05) difference of the indicated group compared to control; horizontal bars indicate significant group differences at the respective time point.

doi:10.1371/journal.pone.0074839.g002
culture of physiologically sterile material (catheter urine sample, CSF and bronchoalveolar lavage).

Blood samples for cytokine measurement were immediately processed for plasma separation and stored at \(-280^\circ\)C until analysis. Plasma cytokine concentrations were measured using commercial ELISA kits following the manufacturer’s protocols (R&D Systems).

Urine catecholamine concentrations (noradrenalin, metanephrin, normetanephrin and vanillylmandelic acid) were measured by HPLC of 24-hour collection urine started immediately after study inclusion. Obtained concentrations were normalized to the produced urine volume of the 24 h collection period.

Statistical Analysis

Descriptive statistics and statistical hypothesis tests were performed using Graphpad Prism software (version 6.0b). \(p\) values \(<0.05\) were considered to be statistically significant. Regression analyses and receiver operating characteristic (ROC) curves were calculated using IBM SPSS software (version 21). Binary logistic regression was applied for univariate analysis. Explanatory variables of the univariate analysis with a \(p\) value \(<0.1\) for the respective dependent variable were included for multivariate analysis. Multivariate binary regression analyses were performed using a conditional forward approach by likelihood ratio. Criteria for stepwise analysis were set at 0.05 for inclusion and at 0.1 for exclusion from the model. ROC curves for the combined variables (lymphocytes×NIHSS) were plotted using predicted probabilities of combined predictors from univariate logistic regression models.

Results

Patient Characteristics

In total, 166 subjects were enrolled into the study. 23 patients had a transient ischemic attack (TIA), 70 patients an ischemic stroke and 43 patients an intracerebral hemorrhage. 30 patients with no neurological or immunological disorder were included as control (Table 1). The mean time between symptom-onset and study inclusion (d1) was 11.9 h and did not differ among groups. Approx. 78\% of surviving patients could be examined for follow-up at day 60–90. Baseline variables did not differ between the appropriate groups except for atrial fibrillation that was significantly more frequent in the ischemic stroke group (Table 1). According to the TOAST criteria [18], stroke etiology in the ischemic stroke group was large-artery atherosclerosis in 13\%, cardioembolism in 34\%, small-artery occlusion in 12\%, other in 2\% and undetermined in 39\%.

Humoral Stress Mediators after Acute Cerebrovascular Events

Previous results [12,13,19] indicated an important role of lesion volume on effect size of systemic immune alterations. We therefore dichotomized patients with ischemic stroke and intracerebral hemorrhage to either small or large lesion volumes. Because a defined and validated lesion volume for discrimination does not exist, we used the median of lesion volume in the respective group (ischemic stroke: 20.8 mm\(^3\), ICH: 21.6 mm\(^3\)) to dichotomize between small and large lesions.

Interestingly, we did not observe a significant difference of plasma adrenalin and metanephrin levels in any group and at any time point compared to control (Fig. 1A). Also serum dopamine...
Normetanephrin concentrations were significantly increased after levels were not consistently altered (Fig. S1). However, a significant proportion of patients with large stroke and ICH compared to small strokes. Normetanephrin concentrations were significantly increased after large stroke and in both ICH groups compared to small strokes (Fig. 1A). However, a significant proportion of patients with large stroke and ICH received intensive medical care including catecholamine (mainly norepinephrine) treatment (compare to Table 1). After exclusion of patients receiving catecholamine treatment no significant difference for plasma noradrenalin concentrations already on admission (day 1) in patients having large lesions (Fig. 2B). Plasma concentrations for the pro-inflammatory cytokines IL-6 and IL-1β peaked at 3d after symptom-onset and showed a most pronounced increase after large ICH. Interestingly, large stroke and ICH resulted in a prolonged increase of IL-6 and IL-1β concentration until follow-up, resulting in a still 2-fold increase of IL-1β compared to controls.

### Infection Surrogate Markers and Bacterial Culture Results

Analyses of surrogate markers (fever, c-reactive protein and procalcitonin levels) for bacterial infection within the first week after symptom-onset revealed a high number of pathological results (Fig. 3A). A significantly higher proportion of patients with large ischemic stroke or ICH had an increase in infection markers compared to TIA and/or small strokes, respectively. Up to 60% of patients had fever and nearly 100% of large ischemic and hemorrhagic stroke patients had pathological serum CRP values >5 mg/l. In contrast, a pathological test result for hsPCT (>0.1 ng/ml) was detected in considerably fewer patients (Fig. 3A). Approx. 60% of patients within the large stroke or either ICH group received antibiotic treatment during the first week after onset. Moreover, a significantly higher proportion of these patient groups also received a second, independent course of antibiotic treatment after discharge from hospital (Fig. 3B). Large stroke and both ICH groups also resulted in significantly more positive bacterial culture results than in patients with TIA or small ischemic lesions (Fig. 3C). Remarkably, the proportion of patients with positive bacterial cultures was distinctly lower than indicated by the most widely used infection markers fever and CRP and also considerably lower than in patients receiving antibiotic treatment (compare to Fig. 3A,B).

### Independent Predictors of Lymphocytopenia and Bacterial Infections

To detect independent predictors of the key feature of post-stroke immunosuppression – lymphocytopenia and infection – we performed univariate regression analyses and included explanatory variables with a p value <0.1 into a multivariate regression model. The cutoff value of <13% for relative lymphocytopenia was determined using ROC curve analysis (see below). Logistic regression analysis for the dependent variable lymphocytopenia.
nia <13% on day 1 (admission) included only predictive variables on admission (Table 2). Interestingly, among stress markers only cortisol and noradrenalin levels in all patients had a significant p value (<0.1) while catecholamine concentrations in patients without catecholamine treatment (n = 109) were not significantly correlated with lymphocytopenia. In the univariate logistic regression model for bacterial infections within the first week after admission all values obtained during the first 7d were included (Table 3). Markers of disease severity (NIHSSS, lesion volume, Table 3. Results of univariate binary logistic regression analysis for bacterial infection d2–d7.

|                              | B       | OR (95% CI)          | Std. OR | p value |
|------------------------------|---------|----------------------|---------|---------|
| Gender (male)                | −0.165  | 0.848 (0.385–1.866)  |         | 0.682   |
| Age                          | −0.009  | 0.992 (0.961–1.023)  | 0.897   | 0.592   |
| NIHSSS                       | 0.119   | 1.126 (1.075–1.180)  | 3.402   | <0.001  |
| Volume                       | 0.005   | 1.005 (1.001–1.009)  | 1.620   | 0.010   |
| Catechol. treat.             | 2.649   | 14.143 (5.55–36.05)  | <0.001  |         |
| Mech. ventilation >24 h      | 3.339   | 28.20 (9.152–86.895) | <0.001  |         |

**Medical condition and premedication**

|                              | B       | OR (95% CI)          | Std. OR | p value |
|------------------------------|---------|----------------------|---------|---------|
| Diabetes                     | −0.616  | 0.540 (0.188–1.548)  |         | 0.251   |
| PreCardioVasc                | −0.668  | 0.513 (0.203–1.295)  |         | 0.158   |
| β-AR blocker                 | −0.677  | 0.508 (0.210–1.231)  |         | 0.134   |
| Smoking                      | −0.344  | 0.709 (0.262–1.920)  |         | 0.499   |

**Blood biomarkers at admission (d1)**

|                              | B       | OR (95% CI)          | Std. OR | p value |
|------------------------------|---------|----------------------|---------|---------|
| Lymphocytes (absolute)       | −0.123  | 0.885 (0.836–0.937)  | 0.307   | <0.001  |
| Lymphocytes <13%             | 1.852   | 6.375 (2.688–15.118) | <0.001  |         |
| Noradrenalin                 | 0.000   | 1.000 (1.000–1.000)  | 1.000   | 0.005   |
| Normetanephrin               | 0.009   | 1.009 (1.001–1.016)  | 1.574   | 0.19    |
| Noradrenalin (w/o Norepi.)   | 0.000   | 1.000 (1.000–1.000)  | 1.000   | 0.055   |
| Normetanephrin (w/o Norepi.) | −0.005  | 0.995 (0.980–1.011)  | 1.033   | 0.544   |
| ACTH                         | 0.002   | 1.002 (0.998–1.006)  | 1.198   | 0.386   |
| Cortisol                     | 0.001   | 1.001 (0.999–1.003)  | 1.196   | 0.392   |
| IL-10                        | 0.065   | 1.067 (1.004–1.135)  | 1.826   | 0.037   |
| IL-6                         | 0.010   | 1.010 (1.002–1.017)  | 12.040  | 0.014   |
| IL-1β                        | 0.324   | 1.383 (0.838–2.280)  | 1.419   | 0.204   |

**Infection markers d2–d7 (all negative at d1)**

|                              | B       | OR (95% CI)          | Std. OR | p value |
|------------------------------|---------|----------------------|---------|---------|
| CRP >5 mg/l                  | 2.755   | 15.725 (2.060–120.2) | 0.008   |         |
| Temp. >38°C                  | 1.617   | 5.036 (2.232–11.36)  | <0.001  |         |
| hsPCT (max.)                 | 25.4    | 1.1E +11 (4.6E +6.25E+15) | 1.7E+13 | <0.001  |
| hsPCT ≥0.1 ng/ml             | 3.871   | 48.0 (14.217–162.6)  | <0.001  |         |

|                              | B       | OR (95% CI)          | Std. OR | p value |
|------------------------------|---------|----------------------|---------|---------|
| NIHSSS                       | 0.141   | 1.151 (1.092–1.213)  | 4.267   | <0.001  |
| Age                          | 0.038   | 1.099 (1.099–1.080)  | 1.381   | 0.053   |

Variables in the model: Age, NIHSSS, smoking, catecholamine treatment d1, noradrenaline, cortisol; method: forward (likelihood ratio), p(in) = 0.05, p(out) = 0.10.
doi:10.1371/journal.pone.0074839.t003

Table 4. Results of multivariate binary logistic regression analyses for independent predictors of lymphocytes <13% on day 1.

|                              | Regr. coefficient | OR (95% CI)          | Std. OR | p value |
|------------------------------|-------------------|----------------------|---------|---------|
| NIHSSS                       | 0.141             | 1.151 (1.092–1.213)  | 4.267   | <0.001  |
| Age                          | 0.038             | 1.099 (1.099–1.080)  | 1.381   | 0.053   |

Variables in the model: Age, NIHSSS, volume, smoking, catecholamine treatment d1, noradrenaline, cortisol; method: forward (likelihood ratio), p(in) = 0.05, p(out) = 0.10.
doi:10.1371/journal.pone.0074839.t004

Table 5. Results of multivariate binary logistic regression analyses for independent predictors of bacterial infections during d2–d7.

|                              | Regr. coefficient | OR (95% CI)          | p value |
|------------------------------|-------------------|----------------------|---------|
| Mech. ventilation >24 h      | 2.931             | 18.744 (4.559–77.061) | <0.001  |
| hsPCT >0.1 ng/ml             | 3.247             | 25.710 (6.555–100.831) | <0.001  |

Variables in the model: NIHSSS, volume, catecholamine treatment, noradrenaline, normetanephrin, temp. >38°C, CRP >5 mg/l, lymphocytes <13%, hsPCT >0.1, mech. ventilation; method: forward (likelihood ration), p(in) = 0.05, p(out) = 0.10.
doi:10.1371/journal.pone.0074839.t005
catecholamine treatment, mechanical ventilation) were all significantly correlated with development of bacterial infections. Lymphocytopenia, IL-10 and IL-6 concentrations on day 1 as well as noradrenalin and normetanephrin levels were highly correlated to the subsequent development of bacterial infections (Table 3).

Multivariate binary regression analysis detected NIHSSS and age as independent predictors of lymphocytopenia<13%, but only NIHSSS had a significant p value <0.05 (Table 4). Mechanical ventilation >24 h and hsPCT values >0.1 ng/ml were found as independent predictors of bacterial infections (Table 5). We performed an additional analysis for independent predictors of bacterial infections excluding the obviously correlated infection markers fever, CRP and hsPCT from the model (Table 6) and detected mechanical ventilation and lymphocytopenia on admission as independent predictors.

**Table 6. Results of multivariate binary logistic regression analyses for independent predictors of bacterial infections during d2–d7 excluding obvious infection markers.**

| Bacterial infection d2–d7 (excluding the infection markers fever, CRP and hsPCT) | Regr. coefficient | OR (95% CI) | p value |
|---|---|---|---|
| Mechan. ventilation >24 h | 3.120 | 22.638 (6.457–79.376) | <0.001 |
| Lymphocytes <13% on d1 | 1.417 | 4.126 (1.430–11.907) | 0.009 |

Variables in the model: NIHSSS, volume, catecholamine treatment, noradrenalin, normetanephrin, lymphocytes <13%, mechan. ventilation; method: forward (likelihood ratio), p(in) = 0.05, p(out) = 0.10.

doi:10.1371/journal.pone.0074839.t006

The major findings of our study are that (1) only large ischemic and hemorrhagic strokes lead to increased plasma levels of some catecholamine metabolites and cortisol. (2) Extensive lesions are associated with pronounced lymphocytopenia, increased cytokine secretion and a strong acute phase reaction. (3) Signs of bacterial infection including positive culture results or elevated hsPCT increase after cerebrovascular events. (4) Catecholamine and steroid levels were neither independent predictors of lymphocytopenia nor of bacterial infection. (5) Disease severity (NIHSSS) was the only significant independent predictor of lymphocytopenia. (6) Lymphocytopenia on admission was an independent predictor of subsequent bacterial infections.

The activation of the SNS and the HPA axis and the modulation of the peripheral immune system are both well-known features of stroke [9,14,20–22]. This is the largest study to date investigating a wide panel of hormonal stress mediators. It also studied the previously uncharacterized categories of ICH and TIA. We detected only a relatively minor increase of plasma catecholamine whereas other pathways such as the acute phase reaction or cytokine levels were profoundly activated in the same patients. ACTH and cortisol were already increased on the first day after admission after large ICH and ischemia. A stroke-induced immunosuppression syndrome after brain ischemia was previously characterized by the pathophysiological hallmarks lymphocytopenia, cellular and humoral immune dysfunction and susceptibility to bacterial infections [10,11,16]. The key features of this syndrome also presented with a similar pattern of immune modulation in patients with extensive brain ischemia and hemorrhage. In contrast no significant immune changes were observed in TIA patients.

The current concept of post-stroke immunosuppression makes a causal link between the two phenomena hormonal stress response and immune dysfunction after stroke. Accordingly, stress hormones, particularly catecholamines, would be signaling from the injured brain to immune cells [8,10,11,16]. By now, 11 clinical studies [12,14,19,21,23–29] have investigated aspects of post-stroke immunosuppression in ischemic stroke of which only 5 studies were prospectively designed. Only one trial detected a correlation between stress mediators and lymphocyte number [28]. No clinical study has distinctly identified catecholamines as independent predictors of lymphocyte dysfunction. Notably, neither the experimental landmark publication by Prass et al. [8] nor any other experimental study in the field of post-stroke immunity measured catecholamine levels after stroke. Pharmacological blockade of beta-adrenoreceptors partially prevented the immune changes after severe experimental stroke in Prass’ study [8]. However, sympathetic denervation did not affect splenic cellularity in another report [22]. In view of these limited and partially controversial findings the causal relationship between the stress response, immune dysfunction and infectious complications which has been advocated in numerous reviews of the subject appears doubtful[7,9,11,16,30,31]. Indeed, our detailed and extensive study challenges such a causal relationship as we did not detect an independent correlation of stress mediator plasma levels on one hand and systemic immune modulation and infectious complications on the other hand even in our large study cohort.
Lymphocytopenia is a hallmark phenomenon of immunodepression after both ischemic and hemorrhagic stroke. In the present study, lymphocytopenia was correlated with the severity of brain damage. The signals that may link stroke and lymphocytopenia are currently unknown. Ischemic and hemorrhagic brain lesions induced similar immune changes depending on lesion size. Conceivably, mediators directly released from the injured brain may trigger peripheral immune dysfunction. In this speculative concept, the amount of the released mediator and the extent of immune system modulation depend on the size of the lesion. Consistent with this concept, TIA patients with no parenchymal tissue damage did not have any changes in their immunological status in the present study. Since lesion volume was such a strong predictor of immune changes, we did not investigate individual brain areas previously suggested to be involved in immune control [32].

A clinically important issue is the lack of specific blood markers of infection. Components of the early phase reaction such as CRP, cytokines, and fever are frequently increased after stroke without other evidence of infection [19]. Multivariate logistic regression analysis in this study detected NIHSSS and lymphocytopenia on admission to be independent predictors of subsequent bacterial infections. Indeed, the very good negative predictive value of the discriminators NIHSSS >15 and lymphocytes <13% may serve as a diagnostic tool to avoid unnecessary antibiotic treatment [33,34].

As a limitation of this study, the exploratory nature of the analysis may have limited the power of the statistical tests. Moreover, frequency and mode of testing for bacterial infections (e.g., cultures, chest x-ray) and antibiotic treatment regimens were not predefined but left to the treating physician’s discretion. Therefore, only positive microbiological bacterial culture results were used as the primary infection outcome parameter instead of combined infection scores using radiological or laboratory parameters. Third, we did not assess the direct interaction of sympathetic nerve fibers with immune cells, however, serum catecholamine are believed to reflect a systemic stress response.

In conclusion, our comprehensive analysis of the effects of acute cerebrovascular disorders on stress hormones, immune function and infections challenges the current concept of stress hormone mediated immunodepression after ischemic and hemorrhagic stroke. Stroke severity and lymphocyte number may serve as valuable predictors for early stratification of patients for antibiotic treatment.

Supporting Information

Figure S1 Dopamin plasma levels in patients with cerebrovascular diseases and control patients. Plasma levels of dopamin were measured in control patients and in patients after TIA, ICH or stroke at the indicated time points. A significant reduction was observed only after small infarcts compared to TIA patients and controls at d1 after stroke. Data is presented as median and interquartile range. * indicates significant (p<0.05) difference of the indicated group compared to the control group; horizontal bar indicates significant difference between respective groups.

Figure 4. ROC curve analysis of independent predictors for lymphocytopenia and bacterial infections. (A) ROC curve performance of the independent variables age and NIHSSS for relative lymphocytopenia on admission (day1). (B) ROC curves of the independent predictors of bacterial infections as detected by multivariate regression analysis. NIHSSS and lymphocytes on admission (day 1) and mechanical ventilation and PCT during the first week. Lymphocytes were plotted as probabilities to avoid curve inversion by the negative correlation. (C) Analysis of ROC performance for the combined predictive variables available on admission. AUC: area under the curve. doi:10.1371/journal.pone.0074839.g004

Lymphocytopenia is a hallmark phenomenon of immunodepression after both ischemic and hemorrhagic stroke. In the present study, lymphocytopenia was correlated with the severity of brain damage. The signals that may link stroke and lymphocytopenia are currently unknown. Ischemic and hemorrhagic brain lesions induced similar immune changes depending on lesion size. Conceivably, mediators directly released from the injured brain may trigger peripheral immune dysfunction. In this speculative concept, the amount of the released mediator and the extent of immune system modulation depend on the size of the lesion. Consistent with this concept, TIA patients with no parenchymal tissue damage did not have any changes in their immunological status in the present study. Since lesion volume was such a strong predictor of immune changes, we did not investigate individual brain areas previously suggested to be involved in immune control [32].

A clinically important issue is the lack of specific blood markers of infection. Components of the early phase reaction such as CRP, cytokines, and fever are frequently increased after stroke without other evidence of infection [19]. Multivariate logistic regression analysis in this study detected NIHSSS and lymphocytopenia on admission to be independent predictors of subsequent bacterial infections. Indeed, the very good negative predictive value of the discriminators NIHSSS >15 and lymphocytes <13% may serve as a diagnostic tool to avoid unnecessary antibiotic treatment [33,34].

As a limitation of this study, the exploratory nature of the analysis may have limited the power of the statistical tests. Moreover, frequency and mode of testing for bacterial infections (e.g., cultures, chest x-ray) and antibiotic treatment regimens were not predefined but left to the treating physician’s discretion. Therefore, only positive microbiological bacterial culture results were used as the primary infection outcome parameter instead of combined infection scores using radiological or laboratory parameters. Third, we did not assess the direct interaction of sympathetic nerve fibers with immune cells, however, serum catecholamine are believed to reflect a systemic stress response.

In conclusion, our comprehensive analysis of the effects of acute cerebrovascular disorders on stress hormones, immune function and infections challenges the current concept of stress hormone mediated immunodepression after ischemic and hemorrhagic stroke. Stroke severity and lymphocyte number may serve as valuable predictors for early stratification of patients for antibiotic treatment.

Supporting Information

Figure S1 Dopamin plasma levels in patients with cerebrovascular diseases and control patients. Plasma levels of dopamin were measured in control patients and in patients after TIA, ICH or stroke at the indicated time points. A significant reduction was observed only after small infarcts compared to TIA patients and controls at d1 after stroke. Data is presented as median and interquartile range. * indicates significant (p<0.05) difference of the indicated group compared to the control group; horizontal bar indicates significant difference between respective groups.

(TIF)
Acknowledgments

The authors would like to thank Simone Karcher for excellent technical support.

References

1. Davenport RJ, Dennis MS, Wellwood I, Warlow CP (1996) Complications after acute stroke. Stroke 27: 415–420.
2. Westendorp WF, Nederkorn PJ, Vermeij JD, Dijkstra MG, van de Beck D (2011) Post-stroke infection: A systematic review and meta-analysis. BMC neurology 11.
3. Katzan I, Cebul RD, Husak SH, Dawson NV, Baker DW (2003) The effect of pneumonia on mortality among patients hospitalized for acute stroke. Neurology 60: 620–625.
4. Sellars C, Bowie I, Bagg J, Sweeney MP, Miller H, et al. (2007) Risk factors for chest infection in acute stroke: a prospective cohort study. Stroke 38: 2294–2299.
5. Emaley HC, Smith CJ, Gavin CM, Georgiou RF, Vail A, et al. (2007) Clinical outcome following acute ischemic stroke relates to both activation and autoregulatory inhibition of cytokine production. BMC neurology 7: 5–5.
6. Urra X, Cervera A, Obach V, Climent N, Planas AM, et al. (2009) Monocytes are major players in the prognosis and risk of infection after acute stroke. Stroke 40: 1262–1268.
7. Chamorro A, Urra X, Planas AM (2007) Infection after acute ischemic stroke: a manifestation of brain-induced immunodepression. Stroke 38: 1097–1103.
8. Prass K, Meisel C, Hollich C, Braun J, Halle E, et al. (2003) Stroke-induced immunodeficiency promotes spontaneous bacterial infections and is mediated by sympathetic activation reversal by poststroke T helper cell type 1-like immunostimulation. J Exp Med 198: 725–736.
9. Urra X, Obach V, Chamorro A (2009) Stroke induced immunodepression syndrome: from bench to bedside. Curr Med Res 9: 195–202.
10. Dirnagl U, Klehmert J, Braun J, Harms H, Meisel C, et al. (2007) Stroke-induced immunodepression: experimental evidence and clinical relevance. Stroke 38: 770–773.
11. Meisel C, Schwab JM, Prass K, Meisel A, Dirnagl U (2005) Central nervous system injury-induced immune deficiency syndrome. Nat Rev Neurosci 6: 775–786.
12. Hug A, Dalpke A, Wieczorek N, Giese T, Lorenz A, et al. (2009) Infarct volume is a major determiner of post-stroke immune cell function and susceptibility to infection. Stroke 40: 3226–3232.
13. Liesz A, Hagemann S, Zoche C, Adamek J, Zhou W, et al. (2009) The spectrum of systemic immune alterations after murine focal ischemia: immunodepression versus immunomodulation. Stroke 40: 2849–2856.
14. Chamorro A, Amaro S, Vargas M, Obach V, Cervera A, et al. (2007) Catecholamines, infection, and death in acute ischemic stroke. J Neurol Sci 252: 29–35.
15. Klehmert J, Harms H, Richter M, Prass K, Volk HD, et al. (2009) Stroke-induced immunodepression and post-stroke infections: lessons from the preventive antibacterial therapy in stroke trial. Neuroscience 158: 1184–1193.
16. Chamorro A, Meisel A, Planas AM, Urra X, van de Beck D, et al. (2012) The immunology of acute stroke. Nature reviews Neurology 8: 401–410.
17. Illanes S, Liesz A, Sun L, Dalpke A, Zorn M, et al. (2011) Hematoma size as major modulator of the cellular immune system after experimental intracerebral hemorrhage. Neurosci Lett 490: 170–174.
18. Adams HP, Jr. (1993) Trials of trials in acute ischemic stroke. The Humana Lecture. Stroke 24: 1410–1415.
19. Smith CJ, Emaley HC, Gavin CM, Georgiou RF, Vail A, et al. (2004) Peak plasma interleukin-6 and other peripheral markers of inflammation in the first week of ischemic stroke correlate with brain infarct volume, stroke severity and long-term outcome. BMC Neurol 4: 2–2.
20. Cruse JM, Lewis RE, Bishop GR, Kleisch WF, Gaitan E (1992) Neuromethodology of immunodeficiency promotes spontaneous bacterial infections and is mediated by sympathetic activation reversal by poststroke T helper cell type 1-like immunostimulation. J Exp Med 198: 725–736.
21. Harms H, Reimnitz P, Bohner G, Werlich T, Klingebiel R, et al. (2011) Influence of stroke localization on autonomic activation, immunodepression, and post-stroke infection. Cerebrovasc Dis 32: 552–560.
22. Ajmo CT, Jr., Collier LA, Leonardo CG, Hall AA, Green SM, et al. (2009) Blockade of adrenergic receptors inhibits the splenic response to stroke. Exp Neurol 210: 47–55.
23. Tarkowski E, Naver H, Wallin BG, Blomstrand C, Tarkowski A (1995) Lateralization of T-lymphocyte responses in patients with stroke. Effect of sympatetic dysfunction? Stroke: 26: 57–62.
24. Emaley HC, Smith CJ, Gavin CM, Georgiou RF, Vail A, et al. (2003) An early and sustained peripheral inflammatory response in acute ischemic stroke: relationships with infection and atherosclerosis. J Neuroimmunol 139: 93–101.
25. Haeseler KG, Schmidt WU, Fahring F, Meisel C, Helms T, et al. (2008) Cellular immunodepression preceding infectious complications after acute stroke in humans. Cerebrovasc Dis 25: 50–56.
26. Smith CJ, Emaley HC, Vail A, Georgiou RF, Rothwell NJ, et al. (2006) Variability of the systemic acute phase response after ischemic stroke. J Neurol Sci 251: 77–81.
27. Walter U, Kolbaske S, Pateljij R, Steinhaugen V, Albu-Mugheira M, et al. (2013) Insular stroke is associated with acute sympathetic hyperactivation and immunodepression. Eur J Neurol 20: 153–159.
28. Urra X, Cervera A, Villanors N, Planas AM, Chamorro A (2009) Harms and benefits of lymphocyte subpopulations in patients with acute stroke. Neuroscience 158: 1174–1183.
29. Vogelsengas A, Grunwald U, Langner S, Jack R, Broker BM, et al. (2008) Analysis of lymphocyte subsets in patients with acute stroke and their influence on infection after stroke. Stroke 39: 237–241.
30. Emaley HC, Hopkins SJ (2008) Acute ischemic stroke and infection: recent and emerging concepts. Lancet Neurol 7: 341–353.
31. Braut V, Arumugam TV, Drummond GR, Sohey CG (2012) Importance of T lymphocytes in brain injury, immunodefiency, and recovery after cerebral ischemia. J Cereb Blood Flow Metab 32: 590–611.
32. Diamond B, Tracey KJ (2011) Mapping the immunological homunculus. Proc Natl Acad Sci U S A 108: 3461–3462.
33. Hug A, Murle B, Dalpke A, Zorn M, Liesz A, et al. (2010) Usefulness of Serum Procalcitonin Levels for the Early Diagnosis of Stroke-Associated Respiratory Tract Infections. Neurocrit Care.
34. Gumbinger C, Hug A, Murle B, Berger B, Zorn M, et al. (2012) Early blood-based microbiological testing is ineffective in severe stroke patients. J Neurol Sci.